Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PPM1B | O75688 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351398 | 1.00 | TP53 (0.44) | TP53ALDH1A1GAASMN1; SMN2CHRNB2 | |
| SCHEMBL408809 | 1.00 | TP53 (0.44) | TP53ALDH1A1GAASMN1; SMN2CHRNB2 | |
| SCHEMBL31196542 | 0.92 | ALDH1A1 (0.45) | TP53ALDH1A1GAASMN1; SMN2CHRNB2 | |
| SCHEMBL3288516 | 0.88 | CHRNB2 (0.41) | TP53ALDH1A1GAASMN1; SMN2CHRNB2 | |
| SCHEMBL1660232 | 0.88 | CHRNB2 (0.41) | TP53ALDH1A1GAASMN1; SMN2CHRNB2 | |
| SCHEMBL1660231 | 0.88 | CHRNB2 (0.41) | TP53ALDH1A1GAASMN1; SMN2CHRNB2 | |
| SCHEMBL14305169 | 0.84 | TP53 (0.46) | TP53ALDH1A1GAASMN1; SMN2CHRNB2 | |
| SCHEMBL358775 | 0.84 | GAA (0.47) | TP53ALDH1A1GAASMN1; SMN2CHRNB2 | |
| SCHEMBL17118123 | 0.84 | TP53 (0.46) | TP53ALDH1A1GAASMN1; SMN2CHRNB2 | |
| SCHEMBL5543322 | 0.84 | GAA (0.47) | TP53ALDH1A1GAASMN1; SMN2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 449 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| EP-4709716-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4709722-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4695259-A1 | TRICYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12539295-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4436667-B1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2026-01-21 | — | — | EP | disclosed |
| EP-0656337-A1 | Process for the production of 1,4-cydohexanedimethanol | EASTMAN CHEMICAL COMPANY (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0656334-A1 | Process for the production of cydohexanedimethanol, with preponderance of the trans-isomer | EASTMAN CHEMICAL COMPANY (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0656338-A1 | Vapour phase hydrogenation of esters or lactones to hydroxy compounds | EASTMAN CHEMICAL COMPANY (US) | 1995-06-07 | — | — | EP | disclosed |
| US-5395987-A | Hydrogenation of ester | EASTMAN CHEMICAL COMPANY (US) | 1995-03-07 | — | — | US | disclosed |
| US-5395986-A | Hydrogenation of dialkyl cyclohexanedicarboxylate using copper or group VIII compound catalysts; high trans configuration to cis ratio | EASTMAN CHEMICAL COMPANY (US) | 1995-03-07 | — | — | US | disclosed |
| US-5395991-A | Regeneration of hydrogenation catalyst | EASTMAN CHEMICAL COMPANY (US) | 1995-03-07 | — | — | US | disclosed |
| US-5387753-A | Catalytic hydrogenating vapor stream unsaturated esters, diesters or lactones in presence of coppor containing catalyst , reactivating the copper catalyst by a stream of hydrogen gas free of reactants | EASTMAN CHEMICAL COMPANY (US) | 1995-02-07 | — | — | US | disclosed |
| US-5116862-A | Acetylenic trithiabicyclo(2.2.2)octanes | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-26 | — | — | US | disclosed |
| CN-1030759-A | Agricultural chemical compound | WELLCOME FOUND (GB) | 1989-02-01 | — | — | CN | disclosed |
| EP-0300797-A1 | Pesticidal compounds | ROUSSEL UCLAF (FR) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | TP53 2236/4885ALDH1A1 4348/4885GAA 4657/4885 |
| US-12539295-B2 | IRAK degraders and uses thereof | IRAK2, IRAK4, IRAK3 | TP53 3635/4885ALDH1A1 4004/4885GAA 3648/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | TP53 3456/4885ALDH1A1 3721/4885GAA 4452/4885 |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | TP53 4372/4885ALDH1A1 1393/4885GAA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.